Log in to search using one of your social media accounts:

 

Living With Cancer: A Cancer Researcher Takes Cancer Personally
Dr. C. Anthony Blau, who has multiple myeloma, started a company to crowdsource an individualized approach to his disease. (Source: NYT Health)
Source: NYT Health - February 15, 2018 Category: Consumer Health News Tags: Breast Cancer Clinical Trials Multiple Myeloma Research Tumors Medicine and Health Source Type: news

Quiz: What Newly Approved Drug Treats Bone Metastases in Multiple Myeloma?
Do you know what dose of carfilzomib is associated with an increased incidence of cardiovascular events in multiple myeloma patients? How about the estimated incidence of new myeloma cases in 2018? Test your knowledge in our latest quiz. (Source: CancerNetwork)
Source: CancerNetwork - February 15, 2018 Category: Cancer & Oncology Authors: Cancer Network Editors Tags: Multiple Myeloma Quiz Source Type: news

Results From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeleta... (Source: Amgen News Release)
Source: Amgen News Release - February 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Depth of Response in PETHEMA/GEM Myeloma Trials Depth of Response in PETHEMA/GEM Myeloma Trials
According to this research, minimal residual disease negativity should be considered one of the most relevant clinical endpoints for some populations of patients with MM.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Infection Prophylaxis, Immune Therapies Lead ASH Myeloma Data Infection Prophylaxis, Immune Therapies Lead ASH Myeloma Data
Dr S. Vincent Rajkumar discusses the most promising new treatments reported for multiple stages of myeloma at this year's ASH meeting.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Changes in genes involved in DNA repair and packaging linked to risk of multiple myeloma
(PLOS) Researchers have identified two gene regions that contribute to multiple myeloma, an inherited cancer that occurs in bone marrow, through a new method that makes use of human disease pedigrees. Nicola Camp and Rosalie Waller of the Huntsman Cancer Institute at the University of Utah, and colleagues, report their findings Feb. 1, 2018, in PLOS Genetics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 1, 2018 Category: Cancer & Oncology Source Type: news

ASCO Backs Bone Drugs for Myeloma
(MedPage Today) -- Recommended for patients with or without evidence of lytic damage (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 31, 2018 Category: Endocrinology Source Type: news

Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS ® (carfilzomib) Label
Label Variation to Include Overall Survival Data From Phase 3 ENDEAVOR Trial THOUSAND OAKS, Calif., Jan. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include updated overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial in patients with relapsed or refractory multiple myeloma (KYPROLIS and dexamethasone [Kd] versus Velcade® [bortezomib] and dexamethasone [Vd]). The ENDEAVOR trial ...
Source: Amgen News Release - January 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Monoclonal Gammopathy of Undetermined Significance: Risk for Progression to Cancer, Other Disorders Examined
Monoclonal gammopathy of undetermined significance (MGUS) is associated with an annual 1% risk for progression to multiple myeloma or plasma-cell or lymphoid disorder, and... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 18, 2018 Category: Primary Care Source Type: news

FDA Approves Addition Of Overall Survival Data To KYPROLIS ® (carfilzomib) Label
Phase 3 Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Velcade® (Bortezomib) and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Overall Survival Results Support Use of KYPROLIS in Combination With Dexamethasone as New Standard of Care THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for KYPROLIS&re...
Source: Amgen News Release - January 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Overall Survival Analysis From KYPROLIS ® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Results Support Early Use of KYPROLIS at First Relapse THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial, which demonstrated that the addition of KYPROLIS® (carfilzomib) to lenalidomide and dexamethasone (KRd) reduced the risk of death by 21 percent ver...
Source: Amgen News Release - January 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Patients with blood cancer precursor at risk of developing cancer even after 30 years
(Mayo Clinic) Patients with monoclonal gammopathy of undetermined significance are at risk of progressing to multiple myeloma or a related cancer -- even after 30 years of stability. These are the findings of a study by Mayo Clinic researchers published in the Wednesday, Jan. 17, issue of the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 17, 2018 Category: Cancer & Oncology Source Type: news

Medical News Today: What is hairy cell leukemia and how is it treated?
This article looks at the symptoms, causes, and treatment options for the disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 16, 2018 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Upfront Stem Cell Transplant Remains Standard of Care for Newly Diagnosed Multiple Myeloma Upfront Stem Cell Transplant Remains Standard of Care for Newly Diagnosed Multiple Myeloma
Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 11, 2018 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

FDA Expands Use of Amgen's Blockbuster Drug FDA Expands Use of Amgen's Blockbuster Drug
Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Expands Use of Denosumab to Myeloma Patients FDA Expands Use of Denosumab to Myeloma Patients
Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA expands use of Amgen's blockbuster drug
(Reuters) - Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma. (Source: Reuters: Health)
Source: Reuters: Health - January 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves XGEVA ® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Expansion of Indication Offers Patients a New Treatment Option Approval Based on Safety and Efficacy Data From the Largest International Multiple Myeloma Clinical Trial Ever Conducted THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. The approval is based on...
Source: Amgen News Release - January 5, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Expansion of Indication Offers Patients a New Treatment Option Approval Based on Safety and Efficacy Data From the Largest International Multiple Myeloma Clinical Trial Ever Conducted THOUSAND OAKS, Calif., Jan. 5, 2018 -- (Healthcare Sales & Marketi... Biopharmaceuticals, Oncology, FDA Amgen, XGEVA, denosumab, Multiple Myeloma, bone protection (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 5, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma
THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xgeva (denosumab) to expand the currently... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 5, 2018 Category: Drugs & Pharmacology Source Type: news

Stage-3 myeloma cancer completely ELIMINATED with a turmeric supplement - British Medical Journal
(Natural News) For decades, the medical establishment has colluded with the for-profit cancer industry to smear anyone who talked about herbs, spices or superfoods fighting cancer. Food doesn’t contain “medicine,” we were told by the dishonest establishment. Only FDA-approved toxic medications can “treat” cancer, the propagandists insisted. Yet millions of people across the globe continued... (Source: NaturalNews.com)
Source: NaturalNews.com - January 4, 2018 Category: Consumer Health News Source Type: news

PharmaMar has requested the process of re-examination for Aplidin ® from the EMA
(Pharmamar) PharmaMar (MSE:PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin ® (plitidepsin) for the indication of relapsed and refractory multiple myeloma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 3, 2018 Category: Cancer & Oncology Source Type: news

Important CV Risk Seen With Carfilzomib in Multiple Myeloma Important CV Risk Seen With Carfilzomib in Multiple Myeloma
Carfilzomib, approved for previously treated multiple myeloma, is associated with a significantly greater risk for all-grade and high-grade cardiovascular events and requires vigilance when used.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients
(University of Pennsylvania School of Medicine) The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 28, 2017 Category: Cancer & Oncology Source Type: news

Falls in older adults with multiple myeloma - Wildes TM, Fiala MA.
OBJECTIVE: To examine the prevalence of falls, factors associated with falls and the relationship between falls and survival in older adults with multiple myeloma METHODS: In an analysis of the Surveillance, Epidemiology and End Results (SEER)-Medicare Hea... (Source: SafetyLit)
Source: SafetyLit - December 20, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

CT scans of Egyptian mummies reveal oldest known cases of breast cancer and multiple myeloma
(University of Granada) An international research team has established that the woman with breast cancer died around 2000 B.C., while the man with multiple myeloma died around 1800 B.C. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 20, 2017 Category: International Medicine & Public Health Source Type: news

ASH: Frailty Screening Tool Guides Therapy in Elderly (CME/CE)
(MedPage Today) -- Multiple myeloma treatment reductions among physically weaker patients (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 15, 2017 Category: Primary Care Source Type: news

MMG49 Identified as a New Target in Multiple Myeloma
MMG49 has been identified as a monoclonal antibody that can be targeted using CAR T-cell therapy for patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2017 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Cancer Targets Immuno Oncology Multiple Myeloma News Source Type: news

Daratumumab Ready to Move to Front Line in Multiple Myeloma Daratumumab Ready to Move to Front Line in Multiple Myeloma
The first phase 3 trial in patients with newly diagnosed multiple myeloma found that daratumumab significantly improved progression-free survival when combined with triple therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASH: Daratumumab Aids Newly Diagnosed Multiple Myeloma
Lower risk of disease progression, death for multiple myeloma patients ineligible for transplantation (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 13, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Top Hematologic Cancer News of 2017
In this slide show we highlight some of the top news on hematologic cancers in 2017, including effective therapies for pediatric hematologic malignancies, a variety of FDA approvals, new discoveries in myeloma, and more. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2017 Category: Cancer & Oncology Authors: Cancer Network Editors Tags: Hematologic Malignancies Hematologic Malignancies Year in Review 2017 Source Type: news

DARZALEX ® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 12, 2017 Category: Pharmaceuticals Source Type: news

DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Phase 3 ALCYONE data showed DARZALEX in combination with bortezomib, melphalan and prednisone meaningfully improved progression-free survival and response rates Data featured as late-breaker at ASH 2017 (Abstract #LBA-4) and published in the New England... Biopharmaceuticals, Oncology Janssen Biotech, DARZALEX, daratumumab, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 12, 2017 Category: Pharmaceuticals Source Type: news

New Data for DARZALEX ® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 12, 2017 Category: Pharmaceuticals Source Type: news

C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis
Bone destruction is a hallmark of myeloma and affects 80% of patients. Myeloma cells promote bone destruction by activating osteoclasts. In investigating the underlying mechanism, we found that C-reactive protein (CRP), a protein secreted in increased amounts by hepatocytes in response to myeloma-derived cytokines, activated myeloma cells to promote osteoclastogenesis and bone destruction in vivo. In mice bearing human bone grafts and injected with multiple myeloma cells, CRP bound to surface CD32 (also known as FcRII) on myeloma cells, which activated a pathway mediated by the kinase p38 MAPK and the transcription factor ...
Source: Signal Transduction Knowledge Environment - December 12, 2017 Category: Science Authors: Yang, J., Liu, Z., Liu, H., He, J., Yang, J., Lin, P., Wang, Q., Du, J., Ma, W., Yin, Z., Davis, E., Orlowski, R. Z., Hou, J., Yi, Q. Tags: STKE Research Articles Source Type: news

KYPROLIS ® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Results Highlighted During Oral Presentation at ASH 2017 Addition of KYPROLIS to Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone Regulatory Applications Submitted in the U.S. to add ASPIRE Overall Survival Results to KYPROLIS Label THOUSAND OAKS, Calif., Dec. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of OS, demonstrating that the addition of KYPROLIS® (carfilzomib)...
Source: Amgen News Release - December 11, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

CAR T-cell therapies drive outcomes in lymphoma, myeloma
(American Society of Hematology) For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight the emerging role played by chimeric antigen receptor (CAR) T-cell therapies in helping individuals mount a clinical response and, in some cases, achieve durable remission. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2017 Category: Cancer & Oncology Source Type: news

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study
(Reuters) - More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - December 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Sequencing offers clues to progression toward multiple myeloma
(Dana-Farber Cancer Institute) Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn't show outward symptoms. The next-generation sequencing project 'will help to explain the biology of the disease and how it unfolds through time from asymptomatic stages to symptomatic ones,' said Mark Bustoros, M.D., a postdoctoral fellow in the lab of Irene Ghobrial, M.D. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2017 Category: Cancer & Oncology Source Type: news

Tracking how multiple myeloma evolves by sequencing DNA in the blood
(Dana-Farber Cancer Institute) Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, eventually, deliver more effective treatments. Researchers now have successfully demonstrated techniques to track these alterations over time by analyzing cell-free DNA (cfDNA) found in blood, according to Jens Lohr, M.D., Ph.D., a hematologist and oncologist at Dana-Farber Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2017 Category: Cancer & Oncology Source Type: news

CAR T, immunotherapy bring new hope for multiple myeloma patients
(University of Pennsylvania School of Medicine) Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies. Both of these investigational approaches targeted a receptor called B-Cell Maturation Antigen (BCMA), which is highly expressed in myeloma and thus a promising target for treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 10, 2017 Category: International Medicine & Public Health Source Type: news

Glenmark Pharma begins clinical trial of anti-myeloma drug
The additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti- tumour activity, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 8, 2017 Category: Pharmaceuticals Source Type: news

VDT PACE Effective in Relapsed, Refractory Multiple Myeloma
Minimal response or more in 68.4 percent of patients, partial response or more in 54.4 percent (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 7, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers
Positive Overall Survival Data From Phase 3 ASPIRE Trial on KYPROLIS® (Carfilzomib) in Relapsed Multiple Myeloma to be Highlighted in Oral Presentation Results From Several Abstracts Highlight the Potential of Amgen's Bispecific T Cell Engager (BiTE®) Platform as an Innovative Approach to Treating Blood Cancers FDA Grants Priority Review for BLINCYTO (Blinatumomab) Supplemental Biologics License Application in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Dec. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from 33...
Source: Amgen News Release - December 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news